MedTrace Logo

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

NCT05380349 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-16

No results posted yet for this study

Summary

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

Conditions

  • Newly Diagnosed Glioblastoma

Interventions

DRUG

combinations of up to 3 FDA approved drugs from a panel of compounds

personalized drug combinations

Sponsors & Collaborators

  • Swedish Medical Center

    lead OTHER

Principal Investigators

  • Charles S Cobbs · Ivy Center for Advanced Brain Tumor Treatment

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05380349 on ClinicalTrials.gov